CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer
CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer
复制标题
肿瘤细胞和基质中的 CD109 表达与胰腺癌的进展和预后相关
DOI：
10.1007/s00428-021-03230-2
复制
发表时间：
2021
期刊：
影响因子：
3.5
通讯作者：
Murakumo Yoshiki
中科院分区：
文献类型：
--
作者：
Adachi Kai;Sakurai Yasutaka;Ichinoe Masaaki;Tadehara Masayoshi;Tamaki Akihiro;Kesen Yurika;Kato Takuya;Mii Shinji;Enomoto Atsushi;Takahashi Masahide;Koizumi Wasaburo;Murakumo Yoshiki
CD 109是一种糖基磷脂酰肌醇锚定糖蛋白，其表达在某些类型的恶性肿瘤中上调。据报道，肿瘤细胞中高水平的CD 109与不良预后相关;然而，CD 109基质表达在人类恶性肿瘤中的意义尚未阐明。在这项研究中，我们研究了CD 109在胰腺导管腺癌（PDAC）中的致瘤特性。92例PDAC手术标本的免疫组化分析显示，肿瘤细胞中CD 109阳性表达与PDAC的不良预后显著相关（无病生存期，p= 0.003;总生存期，p= 0.002），并且是PDAC的独立预后因素（无病生存期，p= 0.0173;总生存期，p= 0.0104）。此外，在肿瘤细胞周围的间质中检测到CD 109表达，类似于α-平滑肌肌动蛋白（癌症相关成纤维细胞的组织学标志物）的表达。间质CD 109表达与PDAC中的肿瘤进展显著相关（TNM分期，p= 0.033; N因子，p= 0.024;淋巴浸润，p= 0.028）。此外，联合评估肿瘤细胞和间质中的CD 109可以从整个患者人群中识别出预后较好的患者组。在MIA PaCa-2 PDAC细胞系中，我们证明了CD 109参与肿瘤细胞运动，但不参与PANC-1。因此，CD 109不仅在肿瘤细胞中，而且在间质中参与PDAC的进展和预后，并且可以作为PDAC的有用的预后标志物。
CD109 is a glycosylphosphatidylinositol-anchored glycoprotein, whose expression is upregulated in some types of malignant tumors. High levels of CD109 in tumor cells have been reported to correlate with poor prognosis; however, significance of CD109 stromal expression in human malignancy has not been elucidated. In this study, we investigated the tumorigenic properties of CD109 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis of 92 PDAC surgical specimens revealed that positive CD109 expression in tumor cells was significantly associated with poor prognosis (disease-free survival,p= 0.003; overall survival,p= 0.002), and was an independent prognostic factor (disease-free survival,p= 0.0173; overall survival,p= 0.0104) in PDAC. Furthermore, CD109 expression was detected in the stroma surrounding tumor cells, similar to that of α-smooth muscle actin, a histological marker of cancer-associated fibroblasts. The stromal CD109 expression significantly correlated with tumor progression in PDAC (TNM stage,p= 0.033; N factor,p= 0.024; lymphatic invasion,p= 0.028). In addition, combined assessment of CD109 in tumor cells and stroma could identify the better prognosis group of patients from the entire patient population. In MIA PaCa-2 PDAC cell line, we demonstrated the involvement of CD109 in tumor cell motility, but not in PANC-1. Taken together, CD109 not only in the tumor cells but also in the stroma is involved in the progression and prognosis of PDAC, and may serve as a useful prognostic marker in PDAC.
登录
查看更多内容
影响因子：
4
作者：
Hagiwara S;Sasaki E;Hasegawa Y;Suzuki H;Nishikawa D;Beppu S;Terada H;Sawabe M;Takahashi M;Hanai N
通讯作者：
Hanai N
影响因子：
8
作者：
Hashimoto, M;Ichihara, M;Takahashi, M
通讯作者：
Takahashi, M
影响因子：
24.5
作者：
Neesse, Albrecht;Bauer, Christian Alexander;Gress, Thomas M.
通讯作者：
Gress, Thomas M.
影响因子：
2.2
作者：
Hagikura, Minako;Murakumo, Yoshiki;Takahashi, Masahide
通讯作者：
Takahashi, Masahide
CD109 是培养细胞分泌的外泌体的组成部分
DOI：
--
发表时间：
2016
期刊：
影响因子：
--
作者：
Sakakura H;Hibi H;Takahashi M;Murakumo Y
通讯作者：
Murakumo Y